Form 4: Eli Lilly Director Acquires Shares Under Deferral Plan

J. Erik Fyrwald, a director at Eli Lilly & Co, acquired 13.133 shares of common stock under the company's Directors' Deferral Plan.

Summary

• On May 19, 2025, J. Erik Fyrwald, a director of Eli Lilly & Co, acquired 13.133 shares of common stock.
• The acquisition was made under the Lilly Directors' Deferral Plan, where shares are deferred in lieu of cash compensation.
• The price per share was $755.11.
• Following the transaction, Fyrwald directly owns 72,852.354 shares of Eli Lilly common stock.
• The acquired shares will be settled in shares of common stock following Fyrwald's separation from service.

Sentiment

Score: 7

Explanation: Routine transaction indicating director's continued investment in the company. No major positive or negative implications.

Positives

• The director's participation in the deferral plan demonstrates confidence in the company's future performance.

Future Outlook

The acquired shares will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

Directors often participate in stock deferral plans as part of their compensation, aligning their interests with those of shareholders. This is a common practice among publicly traded companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholder confidence due to the director's increased stake in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, LLY, Form 4, Beneficial Ownership